Companies: 10,795·Total market cap: $144.5T
Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc.

AQSZFOTCHealthcare● Active
$0.00
+$0.00(+136.36%)
Market Cap$344850
P/E Ratio
52W High$0.008
52W Low$0.0001
Overview

Aequus Pharmaceuticals Inc. (AQSZF) Revenue

Annual & quarterly revenue history · segment & region breakdown

AQSZF · revenue · updated Jun 10, 2026

Core revenue metrics

Aequus Pharmaceuticals Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
12 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Aequus Pharmaceuticals Inc. SEC filings · GAAPUpdated: 2026-06-10

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
AQSZF revenue by year · AQSZF revenue history · AQSZF annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Aequus Pharmaceuticals Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Aequus Pharmaceuticals Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Aequus Pharmaceuticals Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

AQSZF revenue · 4 questions

AQSZF's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

AQSZF revenueAQSZF annual revenuewhat is AQSZF revenueAQSZF TTM revenue

Source: FMP · Aequus Pharmaceuticals Inc. SEC filings · GAAP · Aequus Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026